Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corp (NASDAQ: CAMP) delivers pioneering RNA-based therapies targeting genetic diseases through its innovative RAP Platform™. This page provides investors and researchers with verified updates on clinical developments, strategic partnerships, and regulatory milestones.
Access real-time announcements about CAMP4's progress in upregulating gene expression for CNS and liver disorders. Track key updates including clinical trial phases, FDA designations, and collaborative research initiatives with industry leaders like BioMarin.
All content undergoes rigorous verification to ensure compliance with financial reporting standards. Bookmark this page for centralized access to earnings reports, therapy pipeline advancements, and scientific publications related to regRNA modulation technologies.
CalAmp (Nasdaq: CAMP) announced the release date of its fiscal 2023 fourth quarter and full-year financial results, set for April 27, 2023, after market close. The company will hold a conference call at 5:00 p.m. Eastern to discuss these results, accessible via a webcast on their Investor Relations page. Investors can dial in using the provided phone numbers for participation.
With over 10 million active edge devices and more than 275 patents, CalAmp continues to be a leader in telematics, offering solutions that help over 14,000 organizations improve operational efficiency and compliance. They are focused on enhancing asset tracking and visibility for clients worldwide.
CalAmp (Nasdaq: CAMP), a leading connected intelligence company, announced a restructuring plan aimed at reducing approximately 8% of its workforce to align better with its Software and Subscription Services (S&SS) business model. CEO Jeff Gardner emphasized that this decision, though difficult, is necessary to accelerate business model conversion and enhance profitability. The company assures that these reductions will not impact sales initiatives and are intended to support ongoing efforts to secure new customers globally.
CalAmp (Nasdaq: CAMP) announced that its President and CEO, Jeff Gardner, along with CFO Jikun Kim and SVP of Finance Cindy Zhang, will participate in the 25th Annual Needham Growth Conference on January 10, 2023, at the Lotte New York Palace Hotel. They are set to present at 3:45 p.m. ET and will be available for investor meetings throughout the day. A live video webcast and archived presentation will be accessible on CalAmp's Investor Relations website.
CalAmp (CAMP) reported an 8% increase in total revenue to $78.9 million for Q3 FY2023, outperforming expectations due to improved supply and backlog shipment. Software and Subscription Services (S&SS) revenue rose 11% to $49.3 million, accounting for 62% of total revenue. The remaining performance obligations increased 20% to $252 million. Although gross margin declined to 33.7% due to higher component costs, the company expects improvements in Q4. A net loss reduced to $4.7 million from $7.5 million in the prior quarter.
FAQ
What is the current stock price of Camp4 Therapeutics (CAMP)?
What is the market cap of Camp4 Therapeutics (CAMP)?
